Systemic gene therapy with interleukin-13 attenuates renal ischemia-reperfusion injury

Kidney International

Volumn 73, Issue 12, 2008, Pages 1364-1373

  Sandovici, M ^a   Henning, R H ^a   Van Goor, H ^a   Helfrich, W ^a   De Zeeuw, D ^a   Deelman, L E ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Gene therapy; Ischemia reperfusion; Kidney

Indexed keywords

ADENOVIRUS VECTOR; ALPHA SMOOTH MUSCLE ACTIN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; INTERLEUKIN 13; INTERLEUKIN 13 RECEPTOR; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 2; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; TUMOR NECROSIS FACTOR ALPHA;

ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL DAMAGE; CELL PROLIFERATION; CONTROLLED STUDY; GENE THERAPY; HISTOLOGY; HISTOPATHOLOGY; INTERSTITIAL NEPHRITIS; KIDNEY FAILURE; KIDNEY ISCHEMIA; KIDNEY TUBULE EPITHELIUM; MALE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REPERFUSION INJURY; VIRAL GENE DELIVERY SYSTEM;

EID: 44449125224     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2008.18     Document Type: Article

References (57)

1. Shoskes DA, Halloran PF. Delayed graft function in renal transplantation: etiology, management and long-term significance. J Urol 1996; 155: 1831-1840.
2. Kouwenhoven EA, de Bruin RW, Bajema IM et al. Cold ischemia augments allogeneic-mediated injury in rat kidney allografts. Kidney Int 2001; 59: 1142-1148.
3. Halloran PF, Homik J, Goes N et al. The 'injury response': a concept linking nonspecific injury, acute rejection, and long-term transplant outcomes. Transplant Proc 1997; 29: 79-81.
4. Forbes JM, Hewitson TD, Becker GJ et al. Ischemic acute renal failure: long-term histology of cell and matrix changes in the rat. Kidney Int 2000; 57: 2375-2385.
5. Gueler F, Gwinner W, Schwarz A et al. Long-term effects of acute ischemia and reperfusion injury. Kidney Int 2004; 66: 523-527.
6. Bonventre JV, Weinberg JM. Recent advances in the pathophysiology of ischemic acute renal failure. J Am Soc Nephrol 2003; 14: 2199-2210.
7. Bonventre JV, Zuk A. Ischemic acute renal failure: an inflammatory disease? Kidney Int 2004; 66: 480-485.
8. Klausner JM, Paterson IS, Goldman G et al. Postischemic renal injury is mediated by neutrophils and leukotrienes. Am J Physiol 1989; 256: F794-F802.
9. Okusa MD. The inflammatory cascade in acute ischemic renal failure. Nephron 2002; 90: 133-138.
10. Takada M, Nadeau KC, Shaw GD et al. The cytokine-adhesion molecule cascade in ischemia/reperfusion injury of the rat kidney. Inhibition by a soluble P-selectin ligand. J Clin Invest 1997; 99: 2682-2690.
11. Ysebaert DK, De Greef KE, Vercauteren SR et al. Identification and kinetics of leukocytes after severe ischaemia/reperfusion renal injury. Nephrol Dial Transplant 2000; 15: 1562-1574.
12. Persy VP, Verhulst A, Ysebaert DK et al. Reduced postischemic macrophage infiltration and interstitial fibrosis in osteopontin knockout mice. Kidney Int 2003; 63: 543-553.
13. Coulson MT, Jablonski P, Howden BO et al. Beyond operational tolerance: effect of ischemic injury on development of chronic damage in renal grafts. Transplantation 2005; 80: 353-361.
14. Minty A, Chalon P, Derocq JM et al. Interleukin-13 is a new human lymphokine regulating inflammatory and immune responses. Nature 1993; 362: 248-250.
15. Berkman N, John M, Roesems G et al. Interleukin 13 inhibits macrophage inflammatory protein-1 alpha production from human alveolar macrophages and monocytes. Am J Respir Cell Mol Biol 1996; 15: 382-389.
16. Yanagawa H, Sone S, Haku T et al. Contrasting effect of interleukin-13 on interleukin-1 receptor antagonist and proinflammatory cytokine production by human alveolar macrophages. Am J Respir Cell Mol Biol 1995; 12: 71-76.
17. Evans PC, Kilshaw PJ. Interleukin-13 protects endothelial cells from apoptosis and activation: association with the protective genes A20 and A1. Transplantation 2000; 70: 928-934.
18. Relic B, Guicheux J, Mezin F et al. Il-4 and IL-13, but not IL-10, protect human synoviocytes from apoptosis. J Immunol 2001; 166: 2775-2782.
19. Kato A, Okaya T, Lentsch AB. Endogenous IL-13 protects hepatocytes and vascular endothelial cells during ischemia/reperfusion injury. Hepatology 2003; 37: 304-312.
20. Matsukawa A, Hogaboam CM, Lukacs NW et al. Expression and contribution of endogenous IL-13 in an experimental model of sepsis. J Immunol 2000; 164: 2738-2744.
21. Nicoletti F, Mancuso G, Cusumano V et al. Prevention of endotoxin-induced lethality in neonatal mice by interleukin-13. Eur J Immunol 1997; 27: 1580-1583.
22. Yoshidome H, Kato A, Miyazaki M et al. IL-13 activates STAT6 and inhibits liver injury induced by ischemia/reperfusion. Am J Pathol 1999; 155: 1059-1064.
23. Ke B, Shen XD, Lassman CR et al. Interleukin-13 gene transfer protects rat livers from antigen-independent injury induced by ischemia and reperfusion. Transplantation 2003; 75: 1118-1123.
24. Kawakami K, Taguchi J, Murata T et al. The interleukin-13 receptor alpha2 chain: an essential component for binding and internalization but not for interleukin-13-induced signal transduction through the STAT6 pathway. Blood 2001; 97: 2673-2679.
25. Elnaggar R, Hanawa H, Liu H et al. The effect of hydrodynamics-based delivery of an IL-13-Ig fusion gene for experimental autoimmune myocarditis in rats and its possible mechanism. Eur J Immunol 2005; 35: 1995-2005.
26. Woods JM, Amin MA, Katschke KJ et al. Interleukin-13 gene therapy reduces inflammation, vascularization, and bony destruction in rat adjuvant-induced arthritis. Hum Gene Ther 2002; 13: 381-393.
27. Nabbe KC, van Lent PL, Holthuysen AE et al. Local IL-13 gene transfer prior to immune-complex arthritis inhibits chondrocyte death and matrix-metalloproteinase-mediated cartilage matrix degradation despite enhanced joint inflammation. Arthritis Res Ther 2005; 7: R392-R401.
28. Dmitriev I, Krasnykh V, Miller CR et al. An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism. J Virol 1998; 72: 9706-9713.
29. Broekema M, Harmsen MC, Koerts JA et al. Determinants of tubular bone marrow-derived cell engraftment after renal ischemia/reperfusion in rats. Kidney Int 2005; 68: 2572-2581.
30. Rouschop KM, Roelofs JJ, Claessen N et al. Protection against renal ischemia reperfusion injury by CD44 disruption. J Am Soc Nephrol 2005; 16: 2034-2043.
31. Ichimura T, Bonventre JV, Bailly V et al. Kidney injury molecule-1 (KIM-1), a putative epithelial cell adhesion molecule containing a novel immunoglobulin domain, is up-regulated in renal cells after injury. J Biol Chem 1998; 273: 4135-4142.
32. Ke B, Shen XD, Zhai Y et al. Heme oxygenase 1 mediates the immunomodulatory and antiapoptotic effects of interleukin 13 gene therapy in vivo and in vitro. Hum Gene Ther 2002; 13: 1845-1857.
33. Ke B, Shen XD, Lassman CR et al. Cytoprotective and antiapoptotic effects of IL-13 in hepatic cold ischemia/reperfusion injury are heme oxygenase-1 dependent. Am J Transplant 2003; 3: 1076-1082.
34. Brodsky SV, Yamamoto T, Tada T et al. Endothelial dysfunction in ischemic acute renal failure: rescue by transplanted endothelial cells. Am J Physiol Renal Physiol 2002; 282: F1140-F1149.
35. van Goor H, Ding G, Kees-Folts D et al. Macrophages and renal disease. Lab Invest 1994; 71: 456-464.
36. Cugini D, Azzollini N, Gagliardini E et al. Inhibition of the chemokine receptor CXCR2 prevents kidney graft function deterioration due to ischemia/reperfusion. Kidney Int 2005; 67: 1753-1761.
37. Thurman JM, Lenderink AM, Royer PA et al. C3a is required for the production of CXC chemokines by tubular epithelial cells after renal ischemia/reperfusion. J Immunol 2007; 178: 1819-1828.
38. Takada M, Nadeau KC, Shaw GD et al. Prevention of late renal changes after initial ischemia/reperfusion injury by blocking early selectin binding. Transplantation 1997; 64: 1520-1525.
39. Etter H, Althaus R, Eugster HP et al. IL-4 and IL-13 downregulate rolling adhesion of leukocytes to IL-1 or TNF-alpha-activated endothelial cells by limiting the interval of E-selectin expression. Cytokine 1998; 10: 395-403.
40. Donnahoo KK, Shames BD, Harken AH et al. Review article: the role of tumor necrosis factor in renal ischemia-reperfusion injury. J Urol 1999; 162: 196-203.
41. Donnahoo KK, Meng X, Ayala A et al. Early kidney TNF-alpha expression mediates neutrophil infiltration and injury after renal ischemia-reperfusion. Am J Physiol 1999; 277: R922-R929.
42. Kuziel WA, Morgan SJ, Dawson TC et al. Severe reduction in leukocyte adhesion and monocyte extravasation in mice deficient in CC chemokine receptor 2. Proc Natl Acad Sci USA 1997; 94: 12053-12058.
43. Furuichi K, Wada T, Iwata Y et al. CCR2 signaling contributes to ischemia-reperfusion injury in kidney. J Am Soc Nephrol 2003; 14: 2503-2515.
44. Ohta TM, Kasama T, Hanyuuda M et al. Interleukin-13 down-regulates the expression of neutrophil-derived macrophage inflammatory protein-1 alpha. Inflamm Res 1998; 47: 361-368.
45. Colotta F, Re F, Muzio M et al. Interleukin-13 induces expression and release of interleukin-1 decoy receptor in human polymorphonuclear cells. J Biol Chem 1994; 269: 12403-12406.
46. Girard D, Paquin R, Naccache PH et al. Effects of interleukin-13 on human neutrophil functions. J Leukoc Biol 1996; 59: 412-419.
47. Reglier-Poupet H, Hakim J, Gougerot-Pocidalo MA et al. Absence of regulation of human polymorphonuclear oxidative burst by interleukin-10, interleukin-4, interleukin-13 and transforming growth factor-beta in whole blood. Eur Cytokine Netw 1998; 9: 633-638.
48. Sozzani P, Cambon C, Vita N et al. Interleukin-13 inhibits protein kinase C-triggered respiratory burst in human monocytes. Role of calcium and cyclic AMP. J Biol Chem 1995; 270: 5084-5088.
49. Deckers JG, De Haij S, van der Woude FJ et al. IL-4 and IL-13 augment cytokine- and CD40-induced RANTES production by human renal tubular epithelial cells in vitro. J Am Soc Nephrol 1998; 9: 1187-1193.
50. Van Den Berg JG, Aten J, Annink C et al. Interleukin-4 and -13 promote basolateral secretion of H(+) and cathepsin L by glomerular epithelial cells. Am J Physiol Renal Physiol 2002; 282: F26-F33.
51. Kitching AR, Turner AL, Wilson GR et al. Endogenous IL-13 limits humoral responses and injury in experimental glomerulonephritis but does not regulate Th1 cell-mediated crescentic glomerulonephritis. J Am Soc Nephrol 2004; 15: 2373-2382.
52. Spicer ST, Ha H, Boyd RA et al. Il-4 therapy prevents the development of proteinuria in active Heymann nephritis by inhibition of Tc1 cells. J Immunol 2001; 167: 3725-3733.
53. He TC, Zhou S, da Costa LT et al. A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci USA 1998; 95: 2509-2514.
54. Reynolds P, Dmitriev I, Curiel D. Insertion of an RGD motif into the HI loop of adenovirus fiber protein alters the distribution of transgene expression of the systemically administered vector. Gene Ther 1999; 6: 1336-1339.
55. Sandovici M, Deelman LE, Smit-van Oosten A et al. Enhanced transduction of fibroblasts in transplanted kidney with an adenovirus having an RGD motif in the HI loop. Kidney Int 2006; 69: 45-52.
56. van Goor H, Fidler V, Weening JJ et al. Determinants of focal and segmental glomerulosclerosis in the rat after renal ablation. Evidence for involvement of macrophages and lipids. Lab Invest 1991; 64: 754-765.
57. Sandovici M, Henning RH, Hut RA et al. Differential regulation of glomerular and interstitial endothelial nitric oxide synthase expression in the kidney of hibernating ground squirrel. Nitric Oxide 2004; 11: 194-200.